Authors
Latest:
Dr. Bradley on Radiation Therapy in Lung CancerJeffrey D. Bradley, MD, Professor, Radiation Oncology, Washington University School of Medicine in St. Louis, discusses ongoing research involving radiation therapy for lung cancer.
Latest:
Dr. Lancet on CPX-351 in Elderly Patients With AMLJeffrey E. Lancet, MD, medical oncologist, Moffitt Cancer Center, discusses results of a randomized phase III study comparing the efficacy of CPX-351 (Vyxeos) versus daunorubicin (7+3) plus cytarabine in older patients with newly diagnosed, high-risk acute myeloid leukemia (AML).
Latest:
Radiation Dose Escalation to the Tumor-Arterial Interface of Locally Advanced and Borderline Resectable Pancreatic CancerAn integrated boost with conventional fractionation to the tumor-arterial interface is unlikely to lead to downstaging in borderline resectable and locally advanced pancreatic cancer.
Latest:
Dr. Humphrey on Mogamulizumab for Cutaneous T-Cell LymphomaJeffrey Humphrey, MD, president, Kyowa Hakko Kirin Pharma, Inc., discusses the benefits of mogamulizumab for the treatment of cutaneous T-cell lymphoma.
Latest:
Dr. Raizer Discusses Proton Therapy for GliomaJeffrey J. Raizer, MD, Co-Director, Northwestern Brain Tumor Institute, Professor in Neurology, Ken and Ruth Davee Department, Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, discusses a study that analyzed the overall survival and toxicity of proton therapy for large-volume re-irradiation for recurrent glioma.
Latest:
Dr. Jeffrey Jones on NCCN Recommendations for Relapsed Patients With CLLJeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, discusses NCCN recommendations for treatment of relapsed patients with chronic lymphocytic leukemia (CLL).
Latest:
Dr. Jones on Studying Venetoclax in R/R CLLJeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University, discuss the interest in studying venetoclax (Venclexta) in a phase II study for patients with chronic lymphocytic leukemia (CLL).
Latest:
Dr. Lancet on CPX-351 Compared to Chemotherapy for Older Adults With AMLDr. Lancet of Moffitt Cancer Center explains the use of CPX-351 treatment compared to induction chemotherapy, for older adult patients with acute myeloid leukemia.
Latest:
Dr. Clarke on Available EGFR TKIs in Frontline Treatment of EGFR+ NSCLCJeffrey M. Clarke, MD, assistant professor of medicine, Duke Cancer Institute, discusses the available EGFR TKIs in the frontline setting for the treatment of patients with EGFR-positive non–small cell lung cancer (NSCLC).
Latest:
Dr. Fowler on Patient Eligibility for Cytoreductive Surgery in Ovarian CancerJeffrey M. Fowler, MD, discusses patient eligibility for cytoreductive surgery in newly diagnosed ovarian cancer.
Latest:
PrimeMD, a Pain Reporting Smartphone Application for Patients Undergoing Head and Neck RadiationA feasibility study of a smartphone application that patients undergoing radiation therapy for head and neck cancer can use to regularly report mucositis symptoms.
Latest:
Dr. Holzbeierlein on the Management of Bladder Cancer GuidelinesJeffrey M. Holzbeierlein, MD, professor, director of Urologic Oncology, Department of Urology, University of Kansas Medical Center, discusses the management guidelines for patients with bladder cancer.
Latest:
Dr. Jeffrey Trent on the Melanoma Dream TeamJeffrey M. Trent, MD, president and research director, Translational Genomics Research Institute, discusses the Stand Up to Cancer-Melanoma Research Alliance Dream Team.
Latest:
Parotid Node Metastases in Locally Advanced Nasopharyngeal and Oropharyngeal Cancer: Implications for Radiotherapy Target Volume DelineationThe ipsilateral parotidean nodes may be at risk of metastatic involvement when bulky ipsilateral level II metastases and multilevel nodal disease are co-existent, possibly due to retrograde lymphatic drainage.
Latest:
Dr. Weitzel on the Identification of Li-Fraumeni SyndromeJeffery Weitzel, MD, discusses the identification of Li-Fraumeni syndrome.
Latest:
Dr. Infante on AM0010 in Patients With RCCJeff R. Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses a phase I study of the novel immunotherapy agent AM0010 and its early promise in patients with renal cell carcinoma.
Latest:
Dr Weber on the Background of the KEYNOTE-942 Trial in High-Risk MelanomaJeffrey S. Weber, MD, PhD, discusses the background for the KEYNOTE-942 trial, which was conducted in resected high-risk melanoma.
Latest:
Dr. Wolf Discusses High-Risk Multiple MyelomaJeffrey Wolf, MD, clinical professor, Department of Medicine, director, Myeloma Program, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses high-risk multiple myeloma.
Latest:
Dr Zonder on the Outcomes of the PERSEUS Trial in Multiple MyelomaJeffrey Zonder, MD, discusses the outcomes of the phase 3 PERSEUS trial in patients with relapsed/refractory multiple myeloma.
Latest:
The Evolution of Frontline Therapy in ALK-Positive Advanced NSCLC: Which ALK TKI to Use Upfront?With several new promising options, Jeffrey Zweig, MD, and Heather Wakelee, MD attempt to better answer the question of which ALK tyrosine kinase inhibitor (TKI) should be favored upfront.
Latest:
Jena French on Combinations With Immunotherapy in Thyroid CancerJena D. French, PhD, instructor of Medicine, Division of Endocrinology, Metabolism and Diabetes, University of Colorado Denver, discusses combination regimens exploring immunotherapy and lenvatinib as treatment for patients with thyroid cancer.
Latest:
Novel Agents Aimed at Disrupting Cancer Metabolism Gain GroundSince the Warburg effect has been observed in the majority of cancer types, many studies have focused on developing therapies that target metabolic pathways.
Latest:
Dr. Crews Reflects on the Achievements of the ACCC During Her PresidencyThe outgoing president of the Association of Community Cancer Centers, Jennie Crews, MD, MMM, FACP reflects on her time as president and the achievements the ACCC made.
Latest:
Dr. Stein on Targeted Therapies for MelanomaJennifer A. Stein, MD, PhD, an associate professor of dermatology at NYU Langone Medical Center, discusses targeted therapies for patients with melanoma.
